Thompson Siegel & Walmsley LLC Biogen Inc. Transaction History
Thompson Siegel & Walmsley LLC
- $6.01 Billion
- Q2 2025
A detailed history of Thompson Siegel & Walmsley LLC transactions in Biogen Inc. stock. As of the latest transaction made, Thompson Siegel & Walmsley LLC holds 323,018 shares of BIIB stock, worth $49.2 Million. This represents 0.67% of its overall portfolio holdings.
Number of Shares
323,018
Previous 257,456
25.47%
Holding current value
$49.2 Million
Previous $35.2 Million
15.15%
% of portfolio
0.67%
Previous 0.59%
Shares
14 transactions
Others Institutions Holding BIIB
# of Institutions
1,021Shares Held
131MCall Options Held
2.87MPut Options Held
2.57M-
Vanguard Group Inc Valley Forge, PA17.3MShares$2.63 Billion0.04% of portfolio
-
Primecap Management CO Pasadena, CA15.8MShares$2.41 Billion1.62% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.21 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.47MShares$1.14 Billion0.04% of portfolio
-
Wellington Management Group LLP Boston, MA4.8MShares$730 Million0.11% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $21.9B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...